New bladder cancer device offered to patients with no other options

NCT ID NCT06877676

APPROVED_FOR_MARKETING Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jul 07, 2026 · Updated 3 times

Summary

This program gives patients with high-risk non-muscle invasive bladder cancer access to TAR-200 before it is officially approved. TAR-200 is a device placed into the bladder that releases medication over time. It is for patients who have tried all other treatments and cannot join a clinical trial.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: TAR-200 (a drug-releasing device inserted into the bladder via a catheter)
What this could lead to: If successful, this could provide a new treatment option for patients with high-risk bladder cancer who have run out of standard therapies.
What could go wrong: This is an expanded access program, not a formal trial, so results are not systematically collected. The treatment may not work for everyone and could have side effects like discomfort or infection from the device insertion.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIGH-RISK NON-MUSCLE INVASIVE BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-invasive bladder urothelial carcinoma Non-Muscle Invasive Bladder Neoplasms superficial urinary bladder carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

NON-MUSCLE INVASIVE BLADDER NEOPLASMS

More trials for these conditions

Other studies related to the condition(s) this trial covers.